Peripheral T-Cell Lymphoma: Time for a T-Cell–Centric Standard of Care
This is an exciting time in the treatment of PTCL, but with this opportunity comes responsibility. The challenge of how to optimize a plethora of promising new therapies for a small number of patients will drive therapeutic decision making for the foreseeable future.
CONCLUSIONS: NRP-1 exhibited higher expression in lymphomas, and it was positively expressed in EBV-positive lymphomas. Moreover, highly expressed NRP-1 can be used as an undesirable independent prognostic factor in NHL. PMID: 31282408 [PubMed - as supplied by publisher]
Abstract Mature B- and T-cell lymphomas are diverse in their biology, etiology, genetics, clinical behavior, and response to specific therapies. Here, we review the principles of diagnostic classification for non-Hodgkin lymphomas, summarize the characteristic features of major entities, and place recent biological and molecular findings in the context of principles that are applicable across the spectrum of mature lymphoid cancers. PMID: 31229154 [PubMed - in process]
Publication date: July 2019Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, Volume 128, Issue 1Author(s): Ms. Alma Avila-HernÁndez, Dr. Abelardo Meneses-GarcÍa, Dr. Javier Portilla-RobertsonExtranodal Natural Killer/T-cell Lymphoma, nasal type (ENKTCL-NT) is an aggressive non-Hodgkin lymphom with poor prognosis, is predominant in Latin-America and Asia, whose validated prognostic model have not yet defined, and the prognostic value of CD30 in this disease remains controversial.ObjectiveThe purpose of this study was to describe clinical, pathological and sociodemographic features and eva...
Conclusion: Our findings demonstrate that NGS-based cfDNA mutation profiling reveals genetic heterogeneity across lymphoma subtypes, with potential implications for the discovery of therapeutic targets, the exploration of genome evolution and the development of risk-adapted treatment.
Conclusion: Our results suggest that fibroblast TIAM2 promotes the invasion and migration of lung cancer cell, and OPG might be one of the main cytokines contributing to this pro-cancer process.
We describe cutaneous SCC of the plantar foot in two patients exposed to high doses of PLD. A 50-year-old man with angiosarcoma received a total PLD dose of 1350 mg/m2 and developed cutaneous SCC of bilateral plantar feet. A 45-year-old woman with cutaneous T-cell lymphoma was treated with a total PLD dose of 1142 mg/m2 with subsequent diagnosis of cutaneous SCC of the right plantar foot. No risk factors for SCC of the plantar foot were identified in either patient. Cutaneous SCC is likely an unreported side effect of prolonged exposure to PLD. An extended duration of hand –foot syndrome from other anti-c...
Many nuclear medicine practices are neglecting to tell patients with diabetes...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT aids in melanoma treatment assessment FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too Prescan tutorial eases patient concerns about PET/CT PET technique could aid diabetic therapy monitoring
Many nuclear medicine practices are neglecting to tell diabetic patients that...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT aids in melanoma treatment assessment FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too Prescan tutorial eases patient concerns about PET/CT PET technique could aid diabetic therapy monitoring
We examined the linkage between these mutations and autoimmune symptoms and disorders, in cases of obvious and suspected LGL leukemia. We then summarized and compared mutations in a set of other rare leukemias that also have JAK/STAT signaling pathway activation brought about by genomic changes. These include T-cell acute lymphoblastic leukemia (T-ALL), T-cell prolymphocytic leukemia (T-PLL), cutaneous T-cell lymphoma (CTCL), select peripheral T-cell lymphoma (PTCL), and adult T-cell leukemia/lymphoma (ATLL). Though STAT3 activation is common in these leukemias, the way in which it is achieved, such as the activating cytok...